Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ublituximab - TG Therapeutics

Next Previous
Drug Profile

Ublituximab - TG Therapeutics

Alternative Names: BRIUMVI; EMAB-6; EMAB-603; LFB-R603; R603; Rituximab biobetter - TG Therapeutics; TG-1101; TG-20; TGTX-1101; Ublituximab-xiiy - TG Therapeutics; Utuxin™

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LFB Biotechnologies; rEVO Biologics
  • Developer Johns Hopkins University; LFB Biotechnologies; Neuraxpharm; TG Therapeutics Inc
  • Class Antineoplastics; Biobetters; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Myasthenia gravis
  • Preregistration Submission Withdrawal Chronic lymphocytic leukaemia
  • Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Neuromyelitis optica; Non-Hodgkin's lymphoma; Richter's syndrome

Most Recent Events

  • 03 Feb 2026 TG Therapeutics plans a phase II/III trial for Multiple sclerosis (In children, In adolescents) in March 2026 (IV) (NCT07220252)
  • 03 Nov 2025 Efficacy and adverse events data from the phase III OLE trial in Multiple sclerosis released by TG Therapeutics
  • 28 Oct 2025 TG Therapeutics plans to launch a new dosing regimen for Multiple sclerosis in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top